News Articles
Jul 08, 2020 San Diego Union-Tribune
San Diego Biotech Snags $137M for Precision Attack on Cancer
Jul 08, 2020 BioWorld
Velosbio Raises $137M Series B for ROR1-targeting Cancer Therapies
Jul 08, 2020 BioCentury
VelosBio Jumps on Megaround Bandwagon with $137M Series B
Jul 08, 2020 MedCity News
VelosBio Raises $137M Series B Round to Support Suite of ROR1-targeting Cancer Drugs
Jul 08, 2020 Endpoints News
Singular Focus on ROR1 Earns VelosBio $137M to Fund PhI ADC and Other Programs
Jul 08, 2020 Wall Street Journal
VelosBio Raises $137 Million Series B Round for Cancer Drug Development
Oct 01, 2018 Wall Street Journal
New Cancer Drugmaker VelosBio Collects $58 Million Series A
Now Leaving The VelosBio Site.
VelosBio Inc. is now a wholly-owned subsidiary of Merck & Co., Inc. (Kenilworth, New Jersey USA)